Real‐World Validation of the Clinical Distinctiveness of IDH‐Mutant Glioblastoma in the SEER Transition Era: A Population‐Based Study Integrating Machine Learning

Abstract

The 2021 WHO classification reclassified “IDH‐mutant glioblastoma (GBM)” as “Astrocytoma, IDH‐mutant, grade 4.” This study aims to provide real‐world validation of this reclassification using the specific ICD‐O‐3 code (9445/3) from the Surveillance, Epidemiology, and End Results (SEER) “Transition Era” (2018–2022) and develop a machine learning (ML)‐based prognostic model.